Replies to post #126890 on Biotech Values

[DewDiligence]

MNTA prospects are terrific if they get a timely generic Copaxone approval; if not, then I would think there are many biotechs with better prospects.

Biotechs with better prospects at an enterprise value of $250M? Which ones?